Contraindicated in patients with known or suspected gastrointestinal obstruction, together with paralytic ileus; may cause spasm of sphincter of Oddi; opioids may well cause increases in serum amylase; watch patients with biliary tract illness, such as acute pancreatitis, for worsening symptoms
lumacaftor/ivacaftor will lower the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
lonapegsomatropin will lower the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
fentanyl will enhance the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Evaluate Just about every patient’s risk for opioid addiction, abuse, or misuse just before prescribing opioid and watch; risks are amplified in patients with a personal or family history of substance abuse (which includes drug or alcohol abuse or addiction) or psychological health issues (eg, major depression); potential for these risks must not prevent good management of pain in almost any given client; patients at greater risk might be prescribed opioids, but use in this sort of patients necessitates intensive counseling about risks and correct usage of opioid sulfate along with intense monitoring for signs of addiction, abuse, and misuse; prescribe the drug in smallest suitable quantity and recommend affected individual on proper disposal of unused drug
Examine the Guidance that Fentanyl come with your nasal spray carefully. This will likely inform you tips on how to utilize the nasal spray that you've got.
enasidenib will decrease the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of. Enasidenib (a weak CYP3A4 inducer) could reduce systemic exposure of CYP3A4 substrates. Observe and alter dose of substrate as clinically indicated.
asenapine transdermal and fentanyl both equally maximize sedation. Stay clear of or Use Alternate Drug. Limit use to patients for whom choice treatment options are insufficient
Carefully keep track of the therapeutic effects and adverse reactions associated with CYP3A-metabolized narcotic analgesics (including potentially lethal respiratory depression) is usually recommended with coadministration.
Acute or critical bronchial bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
Warn patients not to push or operate dangerous machinery Except They're tolerant to effects of drug and understand how they may respond to medication
phenelzine improves toxicity of fentanyl by Other (see comment). Contraindicated. Remark: Keep away from fentanyl in patients who require concomitant administration MAOIs, or within fourteen days of halting an MAOI. Serious and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
Keep away from concomitant utilization of tucatinib with CYP3A substrates, where small concentration changes may well bring on critical or life-threatening toxicities. If unavoidable, cut down CYP3A substrate dose according to products labeling.
If coadministration of CYP3A4 inhibitors with fentanyl is essential, check patients for respiratory depression and sedation at Repeated intervals and consider fentanyl dose changes till stable drug effects are obtained.